Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-04-09 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2017年年度报告
Annual Report Classification · 100% confidence The document is titled '2017 年年度报告' which translates to '2017 Annual Report'. It contains detailed sections typical of an annual report such as company overview, financial data, management discussion and analysis, governance, and financial statements. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. It includes comprehensive financial figures, business overview, risk factors, and governance information. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2017
2018-04-09 Chinese
关于聘任高管及增补非独立董事候选人的公告
Board/Management Information Classification · 95% confidence The document is an announcement from a company about the appointment of senior executives and the nomination of a non-independent director candidate. It details the appointment of two senior vice presidents and the nomination of a board candidate, including their resumes and compliance with legal requirements. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in senior management and board composition. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 2727 characters, which is consistent with an announcement rather than a full report.
2018-04-09 Chinese
关于公司及全资子公司申请综合融资额度及为融资额度内融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Betta Pharmaceuticals regarding the application for a comprehensive financing quota and provision of guarantees within that quota by the company and its wholly-owned subsidiaries. It details the board meeting resolutions, the financing amount, the guarantee limits, and the basic information of the subsidiaries involved. The document includes no financial statements or detailed financial performance data but focuses on financing and guarantee arrangements. It is not a full financial report, audit report, or earnings release. It is a formal announcement about financing and guarantee activities, which fits the Capital/Financing Update (CAP) category.
2018-04-09 Chinese
关于公司募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the company's fundraising (募集资金) activities, including the amount raised, the use of the funds, management of the funds, investment projects funded by the raised capital, and compliance with regulatory requirements. It references specific regulatory guidelines from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, and includes detailed financial figures related to the raised funds and their usage during the 2017 fiscal year. The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds, which aligns with disclosures related to capital raising and fund usage. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and not merely an announcement or certification, and it is not an annual or interim report, nor a regulatory filing or announcement. Therefore, the appropriate classification is CAP.
2018-04-09 Chinese
浙江天册律师事务所关于公司2018年股票期权激励计划的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a 2018 stock option incentive plan of a listed company, 贝达药业股份有限公司. It extensively reviews the legal compliance, procedures, and details of the stock option plan, including eligibility, terms, and regulatory adherence. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital/financing activity (stock option incentive plan). It is not a mere announcement or certification but a detailed legal opinion on a financing-related plan. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8992 characters) and content confirm it is a substantive legal opinion on a financing-related matter, not a simple announcement or regulatory filing.
2018-04-09 Chinese
2018年股票期权激励计划激励对象名单
Remuneration Information Classification · 95% confidence The document is titled as the 2018 stock option incentive plan list for Beday Pharmaceutical Co., Ltd. It lists the names and positions of directors, senior management, and core technical/business personnel along with the number of stock options granted. The content focuses on the allocation of stock options to management and key personnel, which is a form of remuneration information. There is no indication of financial statements, audit results, or meeting minutes. The document is not a report but a detailed list related to executive compensation plans. Therefore, the most appropriate classification is Remuneration Information (DEF 14A). The document length is about 5296 characters, which supports it being a detailed list rather than a brief announcement.
2018-04-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.